From the Center for Experimental Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6100
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() |
---|
Activation of platelets results in shedding of membrane microparticles (MP) with potentially bioactive properties. Platelet MP modulate platelet, monocyte, and vascular endothelial cell function, both by direct effects of MP arachidonic acid (AA) and by its metabolism to bioactive prostanoids. We have previously reported that platelet MP induce expression of cyclooxygenase (COX)-2 and prostacyclin production in monocytes and endothelial cells. To elucidate further the molecular mechanisms that underlie MP-induced up-regulation of COX-2 expression, we investigated the response of a human monocytoid (U-937) cell line to platelet MP stimulation.
In U-937 cells, MP-induced COX-2 expression and eicosanoid formation is prevented by pharmacological inhibitors of protein kinase C (PKC), PI 3-kinase, mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase, and p38 kinase. Treatment with the PI 3-kinase inhibitors wortmannin and LY294002 also blocked MP-induced p42/p44 MAPK, p38, and JNK1 phosphorylation. Conversely, platelet MP stimulation of U-937 cells results in direct activation of PKC, p42/p44 MAPK, p38 kinase, and c-Jun N-terminal kinase (JNK) as well as activation of the transcription factors c-Jun and Elk-1. However, MP failed to activate the cAMP response element.
Activation of U-937 cells by MP induces translocation of classical
(PKC Activation of platelets by agonists, such as collagen and
thrombin, results in shedding of membrane microparticles
(MP)1 from their surface (1).
Formation of MP results from an exocytotic budding process (2, 3) and
may include both procoagulant (4, 5) and anticoagulant (6, 7) proteins
when shed from platelets. Increased circulating concentrations of MP
have been detected in vivo in syndromes of platelet
activation (8, 9). It is likely that the shear forces in areas of
disordered flow would favor MP formation (10, 11).
MP might themselves evoke cellular responses in the immediate
microenvironment of their formation. For instance, activation of
endothelial cells results in MP shedding, which, in turn, activates neutrophils, enhancing their propensity to adhere to endothelium (12).
Recently, we have demonstrated that arachidonic acid (AA) in platelet
MP can influence platelet activation in a PKC-dependent manner and endothelial cell COX-2 expression via transcellular lipid
metabolism (13). The molecular mechanisms by which MP induce such
cellular responses are, however, unknown. The present studies were
designed to delineate the signaling pathways involved in MP-induced
COX-2 activation and prostaglandin formation.
COX is the first rate-limiting enzyme in the synthesis of prostacyclin,
prostaglandins, and thromboxane from arachidonic acid (14). Two
isozymes of COX have been described (15, 16), and both catalyze the
cyclooxygenase-dependent transformation of prostaglandin
G2 from AA and the subsequent peroxidation of prostaglandin
G2 to prostaglandin H2 (17). While COX-1 is
expressed constitutively in most tissues, COX-2 is usually induced as
an immediate early gene by mitogenic or inflammatory stimuli as well as
by ligands that act via G protein- and PKC-mediated pathways (18). More
recent findings link the prostaglandin biosynthetic pathways with
activation of MAPK signaling cascades (19-21).
The MAPK pathway, of which there are three subgroups, is a conserved
eukaryotic signaling cascade that is responsible for mediating the
effects of extracellular stimuli on a wide variety of biological
processes. The extracellular signal-regulated kinases (also termed p42
MAPK and p44 MAPK) and the stress-activated protein kinases (also
termed c-Jun NH2-terminal kinase (JNK)) and p38 (22) are
distinguished by activating signals, substrate specificity, and
cellular responses (23). While the extracellular signal-regulated kinases are predominantly activated by growth factors (24, 25), the
JNKs and p38 MAPKs are activated by stress signals such as inflammatory
cytokines, heat shock, ultraviolet light, and ischemia (26).
It is thought that polyunsaturated fatty acids may influence gene
regulation indirectly, via activation of membrane receptors coupled to
downstream signaling cascades (27) or perhaps via nuclear receptors
(28, 29). We have previously demonstrated that unmetabolized AA in
platelet MP modulates adhesive interactions between monocytes and
endothelial cells (30), a cellular interaction thought to be of
relevance in the early stages of atherogenesis (31). Given that neither
a membrane nor a nuclear receptor with high affinity for AA has been
identified, we thought it of interest to delineate the molecular
mechanisms that underlie this phenomenon.
In the present study, we show that MP AA mimics the effect of MP in
inducing COX-2 expression and prostaglandin formation in U-937 cells.
MP AA activates PKC, p42/p44 MAPK, p38 kinase, JNK1, c-Jun, and Elk-1.
Furthermore, inhibition of PKC, p42/p44 MAPK, p38 kinase, and PI
3-kinase prevents MP-mediated COX-2 expression and prostaglandin
formation. These observations suggest that platelet MP AA may activate
a membrane-linked signaling cascade that culminates in expression of
COX-2 rather than requiring activation of nuclear receptors to regulate
gene expression.
Reagents--
Indomethacin,
N,N-diisopropylethylamine, pentafluorylbenzyl
bromide, EDTA, EGTA, cycloheximide, actinomycin-D, leupeptin, Nonidet
P-40, soybean trypsin inhibitor, and aprotinin were purchased from
Sigma. Phorbol 12-myristate 13-acetate (PMA), LY294002, and wortmannin
were obtained from Biomol Research Laboratories, Inc. (Plymouth
Meeting, PA). The prostacyclin analog, Iloprost, AA, [2H8]AA, TxB2,
[2H4]TxB2, PGE2, and
[2H4]PGE2 were all purchased from
Cayman Chemical Co. (Ann Arbor, MI). GF 109203X (bisindolylmaleimide
I),
N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfinamide (H-89), SB 203580, and forskolin were purchased from Calbiochem. [32P]Orthophosphate (6000-7000 Ci/mmol) and
[ Isolation of Platelets, Preparation of Platelet MP, and Their
Identification--
Platelets were obtained from healthy volunteers as
described previously (13). The volunteers had not taken any medication for at least 14 days. Briefly, blood was collected into a plastic syringe containing 3.8% buffered sodium citrate as anticoagulant (ratio 1:9). Platelet-rich plasma was prepared by centrifugation at
130 × g for 15 min, and platelet-poor plasma by
centrifugation of platelet-rich plasma at 900 × g.
Washed platelets were isolated from platelet-rich plasma after
centrifugation and resuspended in calcium- and magnesium-free Hepes
buffer (pH 7.4). The platelet number was always adjusted to 3 × 108/ml. Platelet aggregation was studied at 37 °C using
washed platelets in a PAP-4 model aggregometer (BIO-DATA Corp.,
Hatboro, PA) in siliconized cuvettes with continuous stirring.
Platelet MP were isolated after platelet aggregation, as described
previously (13). Samples were analyzed on a flow cytometer (FACScan;
Becton Dickinson, Mountain View, CA), and each preparation was assayed
to exclude endotoxin contamination, using the Limulus amebocyte lysate assay. Final endotoxin contamination was always <0.02
unit/mg of protein. MP were also preincubated with polymixin B (50 µg/ml) for 1 h before their addition to U-937 cells to exclude bacterial contamination.
Cell Culture--
U-937 cells, obtained from the American Type
Tissue Culture Collection (Rockville, MD), were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 µg/ml streptomycin, and
100 units of penicillin. They were washed twice with RPMI 1640, and
5 × 105 cells/well were plated into 12-well tissue
culture plates. Cell viability was determined by the trypan blue
exclusion test. Indomethacin (20 µM) was always present
in the medium for all experiments described.
Isolation of Arachidonic Acid--
AA isolation was performed as
described previously (13). Briefly, lipids were extracted according to
a modified version of the method of Bligh and Dyer (32) and separated
as described in our previous publication (13). The free fatty acid
fraction was purified by amino (NH2) column chromatography
(International Sorbent Technology, Glamorgan, United Kingdom) followed
by TLC. The band with the same Rf as standard AA
was extracted from the TLC plate and purified by reverse phase high
performance liquid chromatography. Identification of AA was confirmed
by negative ion chemical ionization mass spectrometry, as described
previously (13).
[2H8]AA Labeling of MP--
To
investigate the possibility that U-937 cells might metabolize the lipid
substrate in the MP, MP were labeled with
[2H8]AA. Platelet-rich plasma was incubated
with 10 µM [2H8]AA for 3 h
at 37 °C, and platelets were harvested after washing to remove
unincorporated [2H8]AA.
[2H8]AA-labeled MP were isolated and added to
U-937 cells for 2, 6, 12, and 24 h to investigate a
time-dependent increase in
[2H7]PGE2 and
[2H8]TxB2 formation. Supernatants
were collected to determine
[2H7]PGE2 and
[2H8]TxB2 concentrations, which
were analyzed by gas chromatography/mass spectrometry (GC/MS) as
described below.
Analysis of COX Expression--
Western blot analysis of COX
proteins was carried out as described previously (13). Briefly, U-937
cells were stimulated with MP (6 µg/ml), the equivalent of 10 µM MP AA (3 µg/ml) and lysed following stimulation for
2, 6, 12, or 24 h. Equal amounts of protein (20 and 40 µg for
COX-1 and COX-2, respectively) were separated by 7% SDS-PAGE and
transferred to nitrocellulose. After blocking the membranes for 2 h with 5% fat-free milk in Tris-buffered saline (Tris-HCl, pH 7.5, 250 mM NaCl, 0.1% Tween 20), they were incubated with mouse
monoclonal antibody directed against either COX-1 or COX-2 at a
dilution of 1:10,000 for 1 h at room temperature. Both antibodies
are specific for their respective enzymes, as described previously (33,
34). Membranes were incubated with sheep anti-mouse IgG conjugated with
horseradish peroxidase at 1:2000 for 1 h at room temperature.
Chemiluminescent substrates were used to reveal positive bands that
were visualized after the exposure to Hyperfilm ECL (Amersham Pharmacia Biotech).
Gas Chromatography/Mass Spectrometry--
GC/MS analysis studies
were performed on a Fisons MD-800 GC/MS (VG Organic, Manchester, UK)
equipped with a split/splitless injector operated in the splitless mode
at 260 °C. The ions monitored were m/z 614 for
TxB2, m/z 618 for
[2H4]TxB2, m/z 622 for
[2H8]TxB2, m/z 624 for
PGE2, m/z 628 for
[2H4]PGE2,
m/z 631 for
[2H7]PGE2, m/z 303 for
AA, and m/z 311 for
[2H8]AA.
Evaluation of PKC Activity--
Expression and purification of
recombinant PKC isozymes are described elsewhere (35). The specific
enzymatic activities of the PKC isoforms used in this study have been
previously described (35). PKC activity was measured using a mixture of
50 mM Tris-HCl, pH 7.4, 2 mM EGTA, 50 µM ATP, [ Analysis of Translocation of PKC Isozymes--
U-937 cells were
treated with different concentrations of MP or MP AA. Cytosolic and
particulate fractions were separated by ultracentrifugation as
described by Szallasi et al. (36), and PKC was evaluated in
both fractions by kinase activity or by Western blotting. Total PKC
activity in each fraction was measured using the conditions described
above but with the addition of PS (100 µg/ml) and PMA (10 µM) to the mixture for maximal stimulation. For Western
blot analysis, samples of the cytosolic and particulate fractions were
subjected to immunoblot analysis using specific antibodies for each PKC
isozyme. Briefly, after incubation with MP or MP AA, U-937 cells were
lysed in ice-cold buffer containing 20 mM Tris-HCl, pH 8.0, 1 mM EDTA, 5 µg/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride, 1 µg/ml leupeptin, and 10 µg/ml aprotinin. The cell lysate was centrifuged at 14,000 × g for 2 min. The
protein content was determined using a microbicinchoninic acid assay
(Pierce) with bovine serum albumin as the standard. Equal amounts of
protein for each fraction (20 µg) were subjected to 10% SDS-PAGE and
transferred to nitrocellulose membranes. Membranes were then blocked
for 2 h with 5% fat-free milk in Tris-buffered saline and
incubated with specific antibodies for PKC Analysis of Expression of p42/p44 MAPK, p38 MAPK, and
JNK--
U-937 cells were cultured for 24 h in RPMI 1640 medium
containing antibiotics and 0.5% heat-inactivated fetal calf serum, and
then treated with MP (30 µg/ml) or MP AA (30 µM) for
various times. After incubation, cells were lysed in ice-cold lysis
buffer containing 20 mM Tris-HCl, pH 8.0, 1 mM
EDTA, 5 µg/ml 4-(2-aminoethyl)-benzenesulfonyl fluoride, 1 µg/ml
leupeptin, 10 µg/ml aprotinin, 10 mM sodium fluoride, and
25 mM sodium pyrophosphate. The cell lysate was centrifuged
at 14,000 × g for 2 min. The supernatant was used for
immunoblotting with specific antibodies for the phosphorylated or total
p42/p44 MAPK, p38 or JNK1/2, using the experimental conditions described by the manufacturer (New England Biolabs). Bands were resolved by chemiluminescence as described above.
Determination of MP-induced COX-2, c-Jun, Elk-1, and CRE
Transcriptional Activation--
To investigate MP-induced COX-2
transcriptional activation, we employed a construct containing a
2.0-kilobase pair fragment of the promoter region of human COX-2,
EcoRI (
U-937 cells (6 × 106) were cultured for 24 h in
RPMI 1640 containing antibiotics and 0.5% heat-inactivated fetal calf
serum, following transfection with the COX-2 promoter to avoid serum induction of COX-2. Cells were also transfected with the truncated form
of the COX-2 promoter containing the CRE sequence or with the
pGL2-Basic vector as a negative control. Transfections were performed
using SuperFECTTM (Qiagen, Valencia, CA) according to the
manufacturer's instructions. Similarly, cells were cotransfected with
luciferase reporter plasmids along with various amounts of c-Jun or
Elk-1 expression plasmids or the pFC-dbd plasmid as a negative control.
Cells were also transfected with the CRE expression plasmid alone or
the pFC-dbd plasmid. Cells were then treated with either MP (30 µg/ml), MP AA (30 µM), or forskolin (10 µM) for the indicated time periods. Following
stimulation, cells were collected, washed with PBS, and lysed in lysis
buffer (Promega). The lysate was centrifuged at 14,000 × g for 2 min, and the supernatant was then assayed for
luciferase activity, using a commercial assay kit (Promega). Luminescence was recorded at 560 nm using a Monolight 2010 luminometer (Analytical Luminescence Laboratory). The protein concentration was
determined (Pierce) and used for normalization of the luciferase assays.
Statistical Analysis--
Results are expressed as mean ± S.E. Statistical comparisons were made by using analysis of variance
with subsequent application of Student's t test, as appropriate.
Induction of Cyclooxygenase Activity by Platelet MP--
Treatment
of U-937 cells with MP induced the expression of COX-2, which was
maximal at 12 h (Fig.
1A). No changes in the
expression of COX-1 were observed after MP treatment (Fig.
1E). Expression of COX-2 protein coincided with an increase
in PGE2 and TxB2 synthesis, as measured in the
supernatant (Table I). This increase was
dose-dependent (data not shown). The EC50
values were 3 and 6 µg/ml of MP protein for PGE2 and
TxB2, respectively. Indomethacin (20 µM),
which is a preferential inhibitor of COX-1, which is expressed
constitutively in U-937 cells, was always present in the medium (39).
Actinomycin D (12 µM) and cycloheximide (5 µg/ml), two
inhibitors of protein synthesis, prevented MP-induced COX-2 expression
(Fig. 1A) as well as production of PGE2 and
TxB2 (Table III). L-745,337 (10 µM), a highly
specific inhibitor of COX-2 activity (40), markedly reduced the ability
of MP to augment PGE2 and TxB2 production (Table I).
MP AA Mimics the Effect of MP on COX-2 Expression--
The fatty
acid fraction isolated from MP was found to account for the increase in
expression of COX-2. AA isolated from this fraction was found to mimic
the kinetics of the COX-2 expression induced by intact MP (Fig.
1C). No changes in COX-1 expression were observed (Fig.
1E). To address further the likelihood that MP-dependent induction of COX-2 was mediated by AA itself
and not by its prostaglandin metabolites, we co-incubated U-937 cells with a stable prostacyclin analogue, Iloprost (100 nM),
with U46619 (1 µM), and with PGE2 (10 µM). Although all three were found to induce COX-2
expression in U-937 cells, the kinetics of protein expression were
substantially different from those evoked by MP. Maximum induction of
COX-2 expression by both U46619 and PGE2 occurred at 6 h, while Iloprost-induced COX-2 was maximal at 24 h (data not
shown). The time course of COX-2 induction by AA, by contrast,
corresponded to that evoked by platelet MP (Fig. 1C).
Since we have previously shown that MP donate AA for transcellular
metabolism in endothelial cells (13), we decided to evaluate whether a
similar transfer mechanism might occur in U-937 cells. When MP loaded
with 10 µM [2H8]AA were added
to indomethacin-treated U-937 cells, both
[2H7]PGE2 and
[2H8]TxB2 were synthesized and
released to the supernatant (Table II).
Thus, MP AA may be used as a substrate for prostaglandin formation by
MP-induced COX-2 in U-937 cells.
PKC, p42/p44 MAPK, p38 Kinase, and PI 3-Kinase Mediate MP-induced
COX-2 Expression--
To address the possible involvement of PKC in
MP-induced U-937 COX-2 and prostaglandin formation, cells were
pretreated with GF 109203X (5 µM), a PKC inhibitor (41).
GF 109203X abolished the MP and the MP AA effect on COX-2 expression,
while the PKA inhibitor H-89 (10 µM) was without effect
(Fig. 1, A and C). However, since GF 109203X does
not inhibit either PKC MP Induce PKC Isozyme Activation--
The observation that GF
109203X prevented MP- and MP AA-induced COX-2 and prostaglandin
formation suggested that MP treatment may lead to PKC activation. We
examined the effect of MP on the translocation of PKC isozymes from
cytosolic to particulate fractions to address further this hypothesis
(45-47). Platelet MP markedly alter the distribution of PKC, as judged
by the evaluation of kinase activity in subcellular fractions. Most of
the PKC activity (approximately 70%) was present in the cytosolic
fraction in unstimulated U-937 cells, as previously observed in
fibroblasts and keratinocytes (33, 43). Treatment of U-937 cells with
MP leads to a dose-dependent reduction in the cytosolic PKC
activity, with a concomitant increase in activity in the particulate
fraction. Total PKC activity in the cytosolic fraction was reduced by
72 ± 3% (n = 3) at the highest concentration of
MP tested (100 µg/ml) (Fig.
2A).
Since PKC comprises a family of at least 11 isoforms with differences
in regulation and subcellular distribution, we evaluated the
translocation of individual PKC isozymes by Western blot analysis. While previous studies have identified PKC
We studied the phosphorylation of PKC substrates to investigate further
MP-induced PKC activation. Phosphorylation in intact cells has also
been employed as an index of PKC activation. It was previously reported
that treatment of monocytes and U-937 cells with PKC activators
increases the phosphorylation of substrates of 120, 85, and 28 kDa (49,
50). There was a marked increase in the phosphorylation state of each
of the three substrates by 312 ± 15, 441 ± 21, and 185 ± 30% (n = 4), respectively, in U-937 cells
radiolabeled with [32P]orthophosphate, 10 min after
stimulation with MP (30 µg/ml) (data not shown). Similar
phosphorylation was observed when the cells were treated with PMA (100 nM) for 10 min. The phosphorylation observed after MP or
PMA treatment was prevented by pretreatment with the PKC inhibitor GF
109203X (5 µM) but not by the PKA inhibitor H-89 (10 µM) (data not shown).
MP AA Mimics the Effect of MP on PKC Activation--
Micromolar
concentrations of AA and other unsaturated fatty acids can directly
activate PKC, at least in vitro (51). We have previously
shown that MP AA mediates PKC-dependent platelet aggregation (13). We treated U-937 cells with AA purified from MP,
fractionated the cells by ultracentrifugation, and measured total PKC
activity in the soluble (cytosolic) and particulate fractions. AA (100 µM) induced the redistribution of PKC activity from
cytosolic to the particulate fractions, as observed for intact MP.
Western blot analysis revealed that AA (100 µM)
translocated all of the PKC isozymes present in U-937 cells from the
cytosolic to the particulate fraction (Fig.
4A). Densitometric analysis of
the bands revealed a loss of immunoreactivity from the cytosolic fractions of 75 ± 9, 57 ± 2, 50 ± 5, and 82 ± 8% for PKC
The effect of MP AA on PKC activation observed in U-937 cells was
corroborated by in vitro kinase assays using recombinant PKC
isozymes expressed in and purified from Sf9 insect cells (35). AA was capable of stimulating PKC MP Induce Activation of p42 and p44 MAPK--
Since PD98059, a
specific inhibitor of MEK (42), prevented MP and MP AA-induced COX-2
activation (Fig. 1, B and D), we turned our
attention to the MAPK signaling cascade. We studied the phosphorylation of MAPK in cell lysates to determine whether MP-induced activation of
COX-2 was consistent with upstream activation of MAPK. We evaluated the
phosphorylation of MAPK using phosphospecific antibodies as an index of
MAPK activation (52-54). Phosphorylation of both p42 and p44 MAPK by
MP (30 µg/ml) was evident as early as 5 min; this declined by 30 min
and returned to basal levels at 1 h (Fig.
5B). Total MAPK levels were
not changed, as judged with a MAPK antibody that recognized both the
phosphorylated and unphosphorylated forms of the enzyme (Fig.
5A).
We addressed the hypothesis that PKC influenced MP-induced
phosphorylation of both p42 and p44 MAPK by pretreating the cells with
GF 109203X (5 µM) for 1 h prior to stimulation.
GF 109203X completely inhibited MP-induced phosphorylation of p42 and
p44 MAPK (Fig. 5B). Likewise, staurosporine (100 nM), a nonspecific PKC inhibitor, also inhibited MP-induced
p42/p44 MAPK phosphorylation (data not shown). Again, it seems likely
that PKC MP Induce Activation of p38 Kinase and JNK--
SB203580, a
specific inhibitor for p38 activation (43), suppressed MP- and MP
AA-induced COX-2 activation (Fig. 1, B and D).
This result suggests that more than one MAPK cascade could be activated
by MP treatment. Therefore, we evaluated the activation of p38 and JNK,
using a similar approach as that used for p42/p44 MAPK. MP induced the
phosphorylation of p38 (Fig.
6B). Activation of p38 was
transient, similar to MP-induced p42/p44 MAPK activation. Maximal
phosphorylation was observed at 5 min, which returned to near basal
levels by 1 h post-MP treatment. Unlike MP-induced p42/p44
activation, however, MP-induced p38 phosphorylation is PKC-independent,
since GF 109203X (5 µM) was without effect (Fig. 6B). Likewise, staurosporine (100 nM), was
ineffective in preventing MP-induced p38 MAPK activation (data not
shown). Pretreatment of the cells with SB203580 (10 µM)
had no effect on MP-induced phosphorylation of p38 (Fig. 6B)
as described previously by Cuenda et al. (43). Similarly,
the MEK1 inhibitor PD98059 (10 µM), failed, as expected,
to inhibit MP-induced p38 phosphorylation (data not shown). Total p38
protein levels were not changed by the MP treatment (Fig.
6A).
MP also induced the phosphorylation of JNK. The dominant form of JNK in
U-937 cells is the 46-kDa form or JNK1 (Fig.
7A) as previously reported
(56). When U-937 cells were treated with MP (30 µg/ml), the level of
phosphorylated JNK1 was significantly elevated within 5 min and
remained so for 9 h (Fig. 7B). Pretreatment of the
cells with GF 109203X (5 µM) did not inhibit MP-induced activation of JNK1 (Fig. 7B). A similar effect was observed
with staurosporine (100 nM) (data not shown). No
pharmacological inhibitors of the JNK pathway are available to our
knowledge.
Inhibition of PI 3-kinase activity prevented MP and MP AA-induced COX-2
activation (Fig. 1, B and D). To determine
whether PI 3-kinase activation is relevant to MP-induced p42/p44 MAPK, p38, and JNK activation, we used the same two pharmacological inhibitors, wortmannin and LY294002 (44). Both inhibitors reduced MP-induced activation of p42/p44 MAPK, p38, and JNK1 activation (Figs.
5B, 6B, and 7B), suggesting that PI
3-kinase is upstream of the MAPK cascades when U-937 cells are
activated by MP.
MP AA Mimics the Effect of MP on MAPK Activation--
U-937 cells
were stimulated with MP AA (30 µM) for the same time
periods as for intact MP. The same pattern of activation was observed
for each of the kinases assayed. Maximal activation of p42/p44 MAPK and
p38 by MP AA was observed at 5 min, declined at 30 min, and reached
nearly basal levels by 1 h (Figs. 5C and 6C,
respectively). Similarly, MP AA also mimicked JNK activation by intact
MP (Fig. 7C). Pharmacological inhibition of PKC, MEK1, p38
MAPK, and PI 3-kinase had similar effects with MP AA as observed for
intact MP, albeit the effects of inhibition of PI 3-kinase on p38 MAPK were somewhat less pronounced in the case of MP AA (Figs.
5C, 6C, and 7C).
MP and MP AA Induce Transcriptional Activation of COX-2, c-Jun, and
Elk-1 but Not CRE--
We investigated whether MP might influence gene
regulation to evaluate further their effects on transcriptional
activation of the COX-2 gene. When transfected U-937 cells were
stimulated with MP (30 µg/ml), COX-2 activity increased significantly
(Fig. 8). This was evident as early as 30 min and peaked at 4 h. A similar pattern of activation was
observed when cells were stimulated with MP AA (30 µM)
(Fig. 8). U-937 cells transfected with the pGL2-Basic vector, which
lacks the promoter region of COX-2, showed little or no luciferase
activity (Fig. 8). Furthermore, we also investigated whether MP could
induce c-Jun or Elk-1 transcriptional activation. The COX-2 promoter
has a CRE to which c-Jun binds (57). Our observations suggested that
Elk-1, a substrate for both extracellular signal-regulated kinases and
JNKs, might also regulate COX-2 expression (58, 59). Both MP and MP AA
induction of c-Jun and Elk-1 was maximal at 4 h, similar to the
kinetics of transcriptional activation of COX-2 by MP or MP AA (Fig.
8). U-937 cells cotransfected with the pFR-Luc reporter plasmid and the
pFC-dbd plasmid showed little or no luciferase activity (Fig. 8). Both
MP and MP AA induced the transcriptional activation of both c-Jun and
Elk-1 as expected. A cross-talk mechanism has been previously reported
between the MAPK and JNK signal transduction pathways in U-937 cells
(60). We analyzed MP- and MP AA-induced activation of CRE (which is
specifically activated by cAMP) by two methods to test the specificity
of our system. In both cases, we failed to see an increase in
luciferase activity, while forskolin, which increases cAMP levels,
induced maximal CRE activation at 14 h in both systems (Fig. 8).
This is consistent with our earlier results with the PKA inhibitor
H-89, which failed to inhibit both MP- and MP AA-induced COX-2
expression (Fig. 1). Thus, MP- and MP AA-induced transcriptional
activation is selective, but the increase in c-Jun activation may not
be related to COX-2 induction in our system.
Activation of p42/p44 MAPK, p38, JNK phosphorylation, and CRE as well
as transcriptional activation of c-Jun, Elk-1, or COX-2 by MP AA was
not altered by indomethacin (20 µM), a nonspecific inhibitor of COX isoforms. Thus, AA, rather than its COX metabolites, predominantly mediates the effects of the lipid fraction of platelet MP
on COX-2 transcription.
MP shed from activated platelets have been shown to influence
cellular function. They circulate in syndromes of platelet activation (61) and may accumulate in areas of disordered blood flow (11). Recently, we have demonstrated that platelet-derived MP may facilitate transcellular delivery of AA, thereby modulating aspects of vascular and platelet function (13). The mechanisms by which MP activate cells
remain poorly defined. Platelet MP influence adhesive interactions between monocytes and endothelial cells (30), a mechanism of potential
relevance to initiation of vascular injury at sites of disordered
laminar blood flow in the early stages of atherogenesis (31).
We have previously shown that MP induce human umbilical vein
endothelial cell expression of COX-2 (13). Similarly, we now demonstrate that platelet MP and MP AA induce COX-2 and prostaglandin formation in U-937 monocytoid cells. The signaling pathways that regulate COX-2 expression are incompletely understood but may differ
for the same agonist between cells and between agonists with a single
cell type (62-64). It is unknown how AA regulates COX-2 expression.
Indeed, since membrane receptors for AA remain to be
identified, it is possible that it may ligate directly
nuclear receptors that would regulate gene transcription. We now
demonstrate that MP AA activates PKC isozymes as well as all three
subgroups of the MAPK cascade. These events culminate in activation of
transcription factors of relevance to expression of COX-2.
MP and MP AA induce PKC isozyme phosphorylation and translocation as
well as direct activation in vitro. Nishizuka and co-workers have previously demonstrated that micromolar concentrations of AA can
activate classical, calcium-dependent PKCs (65). Given that
both MP AA and MP induce an elevation in intracellular calcium in U-937
cells (data not shown) and that calcium has previously been shown to
enhance AA-induced activation of PKC (65), it may be that classical
PKCs are the predominant contributors to PKC-dependent
effects of platelet MP. However, our findings clearly demonstrate that
MP AA also activate novel and atypical PKC isoforms in U-937 cells.
In more recent years, a role for AA in the regulation of MAPK
activation as well as transcriptional activation of c-Jun and Elk-1 has
been proposed (66-68). The kinetics of MP AA-induced p42/p44 MAPK
activation are consistent with previous reports on AA-induced p42/p44
MAPK activation in vitro (67). Particularly notable was the
prolonged activation of JNK1 by MP AA and intact MP. Sustained
activation of JNK has been described in response to some (69) but not
all (70) stimuli.
Induction of COX-2 expression and prostaglandin formation has
previously been associated with activation of the MAPK pathway. For
example, Xie et al. provided evidence for the role of JNK and c-Jun in mediating v-Src-induced COX-2 gene expression (19). Similarly, p38 kinase has been implicated in interleukin-1-stimulated COX-2-dependent prostaglandin production in fibroblasts,
human umbilical vein endothelial cells, and mesangial cells (20, 21). Other elements of the prostaglandin pathway have also been linked with activation of MAPKs. For example, both MAPK and p38 mediate biosynthetic activation of cytosolic phospholipase A2 (71,
72).
We have demonstrated that MP AA can activate three distinct MAPKs
(p42/p44 MAPK, p38, and JNK) in monocytoid cells. Inhibitors of PI
3-kinase inhibit activation of all three kinases by MP AA, whereas
inhibitors of PKC inhibit activation of p42/p44 MAPK but not p38 or
JNK. The mechanisms involved in MP and MP AA activation of PI 3-kinase
are under current investigation. Given that PKC inhibition markedly
reduces MP-induced COX-2-dependent prostanoid formation, it
would seem that the p38 and JNK cascades play a less important role in
this consequence of U-937 cell activation by platelet MP. We also
demonstrate that both MP and MP AA can dramatically induce the
transcriptional activation of the COX-2 gene. However, since MP and MP
AA both failed to induce CRE activation, c-Jun, despite its activation
by both MP and MP AA, is unlikely to influence COX-2 transcription in
our system. The role of Elk-1 remains to be determined. Although we
have focused on MP AA, we do not exclude the possibility of a role for
other constituents of the fatty acid fraction in MP that may be of
relevance to the regulation of COX-2. A preliminary model of events
stimulated by platelet MP is provided in Fig.
9.
), novel (PKC
) and atypical (PKC
and PKC
) isozymes of
PKC from the cytosol to the membrane, with concomitant activation of
downstream MAPK. While MP-induced activation of p42/p44 MAPK and p38
kinase is transient, a sustained activation of JNK1 was observed.
Although PKC activation is required for MP-induced p42/p44 MAPK,
activation of the stress kinases p38 and JNK1 was PKC-independent. The
fatty acid fraction of the MP accounted for these effects, which were
mimicked by MP AA. Rather than acting directly via nuclear receptors,
MP AA activates COX-2-dependent prostaglandin production by
a PKC/p42/p44 MAPK/p38 kinase-sensitive pathway in which PI 3-kinase
plays a significant role. MP AA also stimulates transcriptional
activation of COX-2 as well as c-Jun and Elk-1.
INTRODUCTION
Top
Abstract
Introduction
References
MATERIALS AND METHODS
-32P]ATP (3000 Ci/mmol) were purchased from Amersham
Pharmacia Biotech. Mouse monoclonal antibodies against COX-1 and COX-2
were kindly provided by the late Dr. J. Maclouf (INSERM, Paris,
France). The COX-2 promoter construct was a kind gift from Dr. S. Prescott (University of Utah, Salt Lake City, UT). The
affinity-purified antibodies against PKC
, PKC
, PKC
, and PKC
were purchased from Transduction laboratories (Lexington, KY).
Phosphoplus p42/p44 MAPK, and p38 MAPK antibody kits and the MEK-1
inhibitor 2-(2'-amino-3'-methoxyphenyl)-oxanaphthalen-4-one (PD98059)
were purchased from New England Biolabs (Beverly, MA). Rabbit
polyclonal antibody against nonphosphorylated JNK and mouse monoclonal
antibody against phosphorylated JNK were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). The
PathDetectTM in vivo signal transduction pathway
trans-reporting system was purchased from Stratagene (La
Jolla, CA). The luciferase assay kit and the pGL2-Basic vector were
purchased from Promega (Madison, WI).
-32P]ATP (3 µCi/tube), 15 mM C4H6O4Mg, 10 µM
-pseudosubstrate peptide (RFARKGSLRQKNV) as the
phosphoacceptor, the corresponding PKC isozyme, and increasing
concentrations of AA. No PMA or phosphatidylserine (PS) was added.
Assays were carried out at 30 °C for 5 min. Results are expressed
and normalized as a percentage of the maximum stimulation observed for
each PKC isoform. We selected 100 µg/ml PS alone as a PKC activator
in the case of PKC
and 100 µg/ml PS and 10 µM PMA
for all other PKC isozymes (35).
, -
, -
, or -
,
according to the manufacturer's instructions (Transduction
Laboratories). Membranes were then incubated with sheep anti-mouse IgG
for PKC
and PKC
and sheep anti-rabbit IgG for PKC
and PKC
,
conjugated with horseradish peroxidase, at a 1:5000 dilution for 1 h at room temperature. Bands were resolved using chemiluminescence
(ECL, Amersham Pharmacia Biotech). Densitometric analysis of the bands
in the Western blot was performed with a Scanner Control, version 1.00 (Molecular Dynamics, Inc., Sunnyvale, CA).
1840) to MspA1I (+123) (5 base pairs
upstream of ATG), which was cloned into the HindIII site
upstream of the Photinus pyralis (firefly) luciferase gene
in the pGL2-Basic vector (Promega) after linker ligation. This COX-2
construct has been previously described in more detail (37). We
employed two methods to investigate MP-induced CRE activation. First,
we generated a truncated form of the COX-2 promoter from
87 to +123
by polymerase chain reaction. This fragment contains the previously
identified CRE site (TTCGTCA) (38). We subcloned it into the
HindIII site and the BglII site of the pGL2-Basic
vector. Second, we employed the PathDetect cis-reporting system (Stratagene, La Jolla, CA), which includes a reporter plasmid containing the luciferase reporter gene driven by a basic promoter element (TATA box) plus tandem repeats of the CRE. The pFC-PKA plasmid
driven by a cytomegalovirus promoter and containing the PKA catalytic
subunit was used as a positive control to monitor the activity of CRE.
We also employed the PathDetect trans-reporting system to
investigate MP-induced transcription factor activation. This includes a
pathway-specific fusion trans-activator plasmid, which is an
in-frame fusion of an activation domain and the DNA binding domain of
the yeast trans-activator GAL4. A GAL4-c-Jun-(1-223) plasmid controlled by an SV40 promoter or a GAL4-c-Elk-1-(307-427) plasmid controlled by an MLV promoter fusion protein were employed for
these experiments. MEKK-(380-672) and MEK1 (S218/222E,
32-51) plasmids were used as positive controls to monitor the activity of
c-Jun and Elk-1 respectively. The pFR-Luc reporter plasmid contains a
synthetic promoter with five tandem repeats of the yeast GAL4 upstream
activating sequences that control expression of the firefly luciferase
gene. All experiments involving the COX-2 promoter or a truncated form
of the promoter, employed the pGL2-Basic vector (Promega), which lacks
the COX-2 promoter, as a negative control. The pFC-dbd plasmid
(Stratagene, La Jolla, CA), which lacks the activation domain of either
c-Jun, Elk-1, or CRE but contains a GAL4-dbd-(1-147) domain and is
controlled by an SV40 promoter, was used as a negative control for the
trans- and cis-reporting systems, respectively.
Forskolin (10 µM) was used as a positive stimulus to
monitor the activation of both the COX-2/CRE sequence and the CRE
cis-reporting system.
RESULTS
View larger version (21K):
[in a new window]
Fig. 1.
MP and MP AA stimulate a
time-dependent expression of COX-2, but not of COX-1, in a
PKC-, MAPK-, p38 MAPK-, and PI 3-kinase-dependent manner in
U-937 cells. U-937 cells were treated with MP (6 µg/ml)
(A, B, and E) or MP AA (3 µg/ml) (C,
D, and E) for 0, 2, 6, 12, or 24 h. U-937
cells were incubated with cycloheximide (CHX) (5 µg/ml)
for 1 h before the addition of platelet MP or MP AA. Cells were
co-incubated with 12 µM actinomycin D (ACT)
and either platelet MP or MP AA. H-89 dihydrochloride (H89)
(10 µM), GF 109203X (GF) (5 µM),
PD98059 (PD) (10 µM), SB203580 (SB)
(10 µM), LY294002 (LY) (20 µM),
or wortmannin (Wort) (100 nM) were also added to
the cells for 1 h before the addition of platelet MP or MP AA.
Similar results were obtained in three additional experiments.
PGE2 and TxB2 formation by U-937 cells stimulated with
platelet MP in the presence or absence of the COX-2 inhibitor L-745,337
Effects of [2H8]AA-labeled MP on
[2H8]TxB2 and
[2H7]PGE2 production by U-937 cells
or PKC
, they are unlikely to be involved
in MP-induced COX-2 expression. GF 109203X also inhibited the synthesis
of PGE2 and TxB2 induced by MP, while H-89 was
again ineffective (Table III). Cells were
incubated with PD98059 (10 µM) and SB203580 (10 µM), inhibitors of MEK1 (42) and p38 kinase (43),
respectively, as a first approach to investigate whether the MAPK
cascade could play a potential role in MP- and MP AA-induced COX-2
expression and prostaglandin formation. Pretreatment with each of these
inhibitors resulted in down-regulation of MP and MP AA-induced COX-2
expression (Fig. 1, B and D) and prostaglandin formation (Table III). Likewise, pretreatment of U-937 cells with the
PI 3-kinase inhibitors LY2094002 (20 µM) and wortmannin
(100 nM) (44) abolished the expression of COX-2 induced by
either MP (Fig. 1B) and MP AA (Fig. 1D) as well
as prostaglandin formation (Table III).
Dependence of MP-stimulated prostanoid formation by U-937 cells on PKC,
MAPK, p38, PI 3-kinase, and de novo protein synthesis
View larger version (18K):
[in a new window]
Fig. 2.
MP and MP AA induce translocation of PKC
activity. U-937 cells (5 × 105 cells/ml) were
stimulated with MP (1-100 µg/ml) (A) or MP AA (100 µM) (B) for 10 min. Kinase assays were carried
out at 30 °C for 5 min. Cells were fractionated by
ultracentrifugation for 1 h at 100,000 × g, and
samples were assayed for PKC activity as described under "Materials
and Methods." Results are expressed as mean ± S.E. from three
independent experiments.
, PKC
, and PKC
isozymes in U-937 cells (48), we found that they also express PKC
and PKC
. Very low levels of PKC
were also detected (data not
shown). PKC
(a classical or calcium-dependent PKC), PKC
(a novel or calcium-independent PKC), and PKC
and PKC
(atypical or phorbol ester/diacylglycerol-insensitive PKCs),
translocate from the soluble to the particulate fraction upon MP
stimulation in a concentration-dependent fashion (Fig.
3A). No changes were observed
in the content of total PKC isozymes in total lysates. Densitometric
analysis of the bands revealed a loss of 94 ± 4%, 75 ± 3%, 70 ± 6%, and 92 ± 2% (n = 4) for
cytosolic PKC
, PKC
, PKC
, and PKC
, respectively,
at the highest concentration (100 µg/ml) of MP tested (Fig.
3B). Therefore, translocation of U-937 cell PKC isozymes by
platelet MP does not appear to discriminate among the different PKC
subtypes present in the cell.
View larger version (41K):
[in a new window]
Fig. 3.
MP translocate PKC isozymes. U-937 cells
(5 × 105 cells/ml) were treated with MP (1-100
µg/ml) for 10 min and then fractionated into cytosolic or particulate
fractions as described under "Materials and Methods." Equal amounts
of protein were subjected to 10% SDS-PAGE and analyzed by Western
blotting using antibodies raised against PKC , PKC
, PKC
, and
PKC
(A). B, quantitation of immunoblots by
densitometric analysis. The figure is representative of four
separate blots, and the densitometry values are expressed as mean ± S.E. from four independent experiments.
, PKC
, PKC
, and PKC
, respectively (Fig.
4B). No changes in PKC activity were observed in aliquots of
total lysates.
View larger version (34K):
[in a new window]
Fig. 4.
MP AA translocates PKC isozymes. U-937
cells (5 × 105 cells/ml) were treated with MP AA (100 µM) for 10 min and then fractionated into cytosolic or
particulate fractions as described under "Materials and Methods."
Equal amounts of protein were subjected to 10% SDS-PAGE and analyzed
by Western blotting using antibodies raised against PKC , PKC
,
PKC
, and PKC
(A). Quantitation of immunoblots was by
densitometric analysis (B). The figure is
representative of four separate blots, and the densitometry values are
expressed as mean ± S.E. from four separate experiments.
, -
, and -
in a
concentration-dependent fashion (Table
IV). We did not study MP AA activation of
PKC
, since the purified enzyme was not available. A similar pattern of activation was observed with other PKC enzymes, such as PKC
, which are not present in U-937 cells (data not shown). In
vitro assays, using U-937 cells as a source of PKC, also revealed
that MP AA induces activation of total PKC in U-937 cells (Table IV). Similar results in U-937 cells and in in vitro kinase assays
were observed with AA obtained from a commercial source (Sigma) (data not shown). The PKC inhibitor, GF 109203X (5 µM), totally
abolished MP-induced activation of U-937 PKC and recombinant PKC
and
PKC
. PKC
is insensitive to PKC inhibitors known to interfere with the catalytic domain of this enzyme (Ref. 41, and data not shown).
MP AA stimulates PKC in vitro
, PKC
, or PKC
isozymes purified from
Sf9 insect cells and assayed. GF 109203X was used at a
concentration of 5 µM. Kinase assays were carried out at
30 °C for 5 min, and results are expressed and normalized as
percentage of maximal PKC activation when using as PKC activators 100 µg/ml PS alone for PKC
and 100 µg/ml PS and 10 µM
PMA for all other isozymes. Results are expressed as mean ± S.E.
of four independent experiments.
View larger version (53K):
[in a new window]
Fig. 5.
Activation kinetics and inhibition of p44/p42
MAPK by platelet MP and MP AA. Aliquots of extracts containing 20 µg of protein were loaded on a 10% SDS-PAGE and analyzed by
immunoblot using anti-MAPK antibodies that react with total p42/p44
MAPK to ensure equal protein loading (A) and
phosphoanti-MAPK antibodies that react only with the phosphorylated
forms of p42 MAPK and p44 MAPK (B, C, and
D). U-937 cells (5 × 105/ml) were
stimulated with MP (30 µg/ml) (B) or MP AA (30 µM) (C). Cells were preincubated with GF
109203X (GF) (5 µM), PD98059 (PD)
(10 µM), wortmannin (Wort) (100 nM), or LY294002 (LY) (20 µM) for
1 h prior to stimulation. Down-regulation of PKC was achieved by
pretreatment of the cells with 100 nM PMA for 48 h.
A, B, and C are representative of four
separate blots. D represents control or unstimulated cells
(C) or stimulation of U-937 cells (5 × 105/ml) with MP (30 µg/ml), MP AA (10 µM),
or PMA (100 nM) for 5 min. Cells were pretreated with
LY294002 (LY) (20 µM) for 1 h prior to
stimulation. D is representative of two separate
blots.
and PKC
are not involved, since neither is inhibited by
GF 109203X. Pretreatment of the cells with PMA for 48 h
down-regulated PKC (55) and also totally inhibited the activation of
p42/p44 MAPK by MP (Fig. 5B). Pretreatment of the cells for
1 h with PD98059 (10 µM), an inhibitor of MEK1 (42),
was also found to abolish completely MP-induced p42/p44 MAPK activation
(Fig. 5B). To investigate whether PI 3-kinase is upstream or
downstream of PKC in our system, we pretreated cells with LY294002
before stimulation with PMA. LY294002 failed to inhibit PMA-induced
p44/p42 MAPK phosphorylation, indicating that PI 3-kinase resides
upstream of PKC (Fig. 5D).
View larger version (42K):
[in a new window]
Fig. 6.
Activation kinetics and inhibition of p38 by
platelet MP and MP AA. Aliquots of extracts containing 20 µg of
protein were loaded on a 10% SDS-PAGE and analyzed by immunoblot using
an anti-p38 antibody that reacts with total p38 to ensure equal protein
loading (A), and phosphoanti-p38 antibody that reacts only
with the phosphorylated form of p38 (B and C).
U-937 cells (5 × 105/ml) were stimulated with MP (30 µg/ml) (B) or MP AA (30 µM) (C).
Cells were preincubated with GF 109203X (GF) (5 µM), SB203580 (SB) (10 µM),
wortmannin (Wort) (100 nM), or LY294002 (LY) (20 µM) for 1 h prior to stimulation. The
figure is representative of four separate blots.
View larger version (29K):
[in a new window]
Fig. 7.
Activation kinetics and inhibition of JNK1 by
platelet MP and MP AA. Aliquots of extracts containing 20 µg of
protein were loaded on a 10% SDS-PAGE and analyzed by immunoblot using
anti-JNK antibodies that react with total JNK46 and
JNK52 to ensure equal protein loading (A) and
phosphoanti-JNK antibodies that react only with the phosphorylated
forms of JNK46 and JNK52 (B and
C). U-937 cells (5 × 105/ml) were
stimulated with MP (30 µg/ml) (B) or MP AA (30 µM) (C). Cells were preincubated with GF
109203X (GF) (5 µM), wortmannin
(Wort) (100 nM), or LY294002 (LY) (20 µM) for 1 h prior to stimulation. The
figure is representative of four separate blots.
View larger version (25K):
[in a new window]
Fig. 8.
Effect of platelet MP and MP AA on the
transcriptional activation of COX-2, c-Jun, Elk-1, and CRE in
transfected U-937 cells. U-937 cells (6 × 106
cells) were transfected with either the pGL2-Basic vector as vector
control (A, D), the pGL2-Basic vector containing
2.0 kilobase pairs of the 5' sequence of the COX-2 gene (A),
or the pGL2-Basic vector containing the CRE sequence (TTCGTCA) of the
COX-2 gene (D). Cells were also cotransfected with
GAL4-c-Jun (B), GAL4-c-Elk-1 (C) together with
the pFR-Luc reporter plasmids, or the CRE plasmid alone (E)
as outlined under "Materials and Methods." Cells were transfected
with the pFC-dbd plasmid as vector control in B,
C, and E. Cells were stimulated with MP (30 µg/ml), MP AA (30 µM), or forskolin (10 µM) for the time periods indicated. Luciferase activity
was determined on cell extracts as described under "Materials and
Methods." The results shown are mean ± S.E. of two experiments
for COX-2, three experiments for CRE and COX-2/CRE, and five
experiments for c-Jun and Elk-1. LU, luciferase units.
DISCUSSION
View larger version (16K):
[in a new window]
Fig. 9.
MP-stimulating pathways. This
diagram illustrates the signaling cascades involved in
MP-induced COX-2 expression. For details, see text.
The present observations may also have relevance to the role of
platelet activation in atherogenesis. Thus, laminar shear has been
shown to produce prolonged up-regulation of COX-2 in endothelial cells
(73). Production of prostacyclin, the predominant COX-2 product in
these cells, inhibits platelet activation and adhesive interactions
between circulating blood cells and the endothelium (74). Turbulent
shear, by contrast, fails to up-regulate COX-2 in endothelial cells. A
similar discrepancy of effect is observed with induction of endothelial
nitric-oxide synthase (73). Given that turbulence may mimic the
disordered laminar shear that occurs in vivo at sites of
lesion development, this raises the possibility that a
localized deficiency in prostacyclin and NO may be of functional
relevance to the focal nature of atherogenesis. Thus, disordered shear
forces favor platelet activation and the shedding of MP, an effect that
can only be amplified by a localized, coexistent deficiency of
endogenous platelet inhibitors, such as prostacyclin and NO. We have
shown that MP AA can stimulate directly platelet aggregation and
adhesive interactions involving both platelets and monocytes with
endothelial cells. Furthermore, while disordered shear may impair the
ability of endothelial cells to generate COX-2-dependent
prostacyclin, stimulation of monocyte and platelet TxA2 by
platelet MP would amplify further platelet activation and the adhesive
interactions induced by MP AA.
![]() |
FOOTNOTES |
---|
* This work was supported by National Institutes of Health Grants HL57847 and HL50400 (to G. A. F.) and CA74197 (to M. G. K.) and American Cancer Society Grant RPG-97-092-01-CNE (to M. G. K.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Robinette Foundation Professor of Cardiovascular Medicine. To whom
correspondence should be addressed: Center for Experimental Therapeutics, 905 Stellar-Chance Laboratories, University of
Pennsylvania School of Medicine, Philadelphia, PA 19104-6100. Tel.:
215-898-1185; Fax: 215-573-9135; E-mail:
garret{at}spirit.gcrc.upenn.edu.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: MP, microparticle(s); AA, arachidonic acid; COX, cyclooxygenase; CRE, cyclic AMP response element; JNK, c-Jun NH2-terminal kinase; PKC, protein kinase C; PKA, protein kinase A; MAPK, mitogen-activated protein kinase; MEK, MAPK/extracellular signal-regulated kinase/extracellular signal-regulated kinase; PMA, phorbol 12-myristate 13-acetate; PGE2, prostaglandin E2; TxB2, thromboxane B2; H-89, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfinamide; PD98059, 2-(2'-amino-3'-methoxyphenyl)-oxanaphthalen-4-one; PAGE, polyacrylamide gel electrophoresis; PI, phosphatidylinositol; GC/MS, gas chromatography/mass spectrometry; PS, phosphatidylserine.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() |
---|